Oncogenomics: The Future of Cancer Care

Share Article

Piribo, (http://www.piribo.com) the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report entitled “Oncogenomics: The Future of Cancer Care”

This report analyzes the key advances and challenges associated with translating research efforts into successful, clinically meaningful therapeutic products. The emergence of oncogenomics promises a new era of cancer care. Over the next decade or so, biomedical researchers hope to have fully catalogued all genetic alterations associated with cancer, greatly expanding the number of “druggable” anticancer molecular targets.

Oncogenomics has already seen clinical and market success with a handful of “first-generation” oncogenomic therapeutics such as Herceptin, raising hope and expectations that safer and more effective patient-selected targeted therapeutics will revolutionize cancer therapy and transform cancer into a manageable chronic disease. While patient-selected genomic-based therapy has only recently emerged as a viable clinical practice, many experts argue that it will become crucial not just in clinical practice but as an integral component of targeted drug development.

However, despite the early success stories of Herceptin and Gleevec, many leaders in the field are cautious about the extent to which genomics will truly impact cancer care over the next 10 to 15 years. Employing the right tools, technologies, and strategies will be crucial to realizing the clinical and marketplace opportunities stemming from the burgeoning growth of oncogenomics.

Oncogenomics: The Future of Cancer Care offers insightful evaluation of the following key challenges to achieving this goal and examines current approaches to addressing these issues:

  • Preclinical drug candidate screening needs to be more predictive in order to increase the chance that a targeted drug entering clinical trials will succeed.
  • Patient selection needs to be integrated into targeted drug development and clinical practice.
  • Many pharmaceutical companies remain resistant to the patient-selected targeted drug model.
  • Not all of the targets yielded by the Human Genome Project are “druggable” and it is extremely difficult to determine which genes associated with cancer are consequences, not causes, of cancer.
  • Most tumors involve multiple mutations, which could translate into multiple pathways.

“Oncogenomics: The Future of Cancer Care” is available in hard copy and PDF format from Piribo. For more information, go to: http://www.piribo.com/publications/diseases_conditions/cancer/oncogenomics_cancer_care.html

About Piribo.

Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 3,000 English language titles including, market reports, studies and books and is the UK’s largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Fiona Brown
+44 207 060 7474
Email >